NEW YORK (

TheStreet

) --

Biogen Idec

(Nasdaq:

BIIB

) hit a new 52-week high Friday as it is currently trading at $276.21, above its previous 52-week high of $262 with 1.7 million shares traded as of 9:50 a.m. ET. Average volume has been 1.1 million shares over the past 30 days.

Biogen Idec has a market cap of $58.14 billion and is part of the health care sector and drugs industry. Shares are up 68.2% year to date as of the close of trading on Thursday.

Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. The company has a P/E ratio of 34.6, above the S&P 500 P/E ratio of 17.7.

  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

TheStreet Ratings rates

Biogen Idec

TheStreet Recommends

as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, impressive record of earnings per share growth and compelling growth in net income. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. You can view the full

Biogen Idec Ratings Report

.

See all

52-week high stocks

or get investment ideas from our

investment research center

.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more

.

null